-
Signature
-
Mark A. Wilson, Attorney-in-Fact
-
Issuer symbol
-
NKTR
-
Transactions as of
-
02 Sep 2025
-
Net transactions value
-
-$45,240
-
Form type
-
4
-
Filing time
-
04 Sep 2025, 21:01:15 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| ROBIN HOWARD W |
President & CEO, Director |
C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO |
Mark A. Wilson, Attorney-in-Fact |
04 Sep 2025 |
0001206869 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
NKTR |
Common Stock |
Sale |
$45,240 |
-1,500 |
-2.2% |
$30.16 |
67,840 |
02 Sep 2025 |
Direct |
F1, F2 |
| holding |
NKTR |
Common Stock |
|
|
|
|
|
28 |
02 Sep 2025 |
by spouse |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: